Acute pancreatitis is a rare complication in patients treated with ceftriaxone. Precipitation of ceftriaxone in the bile causes the formation of biliary sludge leading to the development of cholangitis, cholecystitis, or pancreatitis. We treated a patient with acute pancreatitis who developed this condition after the administration of ceftriaxone. A 70-year-old man presented in a drowsy state with fever. He was diagnosed with a liver abscess and treated with intravenously administrated ceftriaxone and metronidazole. He complained of dyspepsia and epigastric pain on the 25th day of ceftriaxone administration. Laboratory examination and abdominal computed tomography revealed biliary pancreatitis. Ceftriaxone-induced acute pancreatitis was suspected, and ceftriaxone administration was immediately discontinued. Two days later, serum amylase and lipase levels recovered to within reference range, and he showed rapid resolution of symptoms. We concluded that ceftriaxone results in the formation of biliary sludge and causes serious adverse events such as cholecystitis, cholangitis and biliary pancreatitis. Korean J Pancreas Biliary Tract 2018;23(2):82-86 
INTRODUCTION
Ceftriaxone is a widely used third-generation cephalosporin showing high antimicrobial activity and a long half-life.
Complications of the long-term use of high dose include biliary sludge formation and cholelithiasis. 1 The risk of ceftriaxone-induced cholelithiasis is higher in patients with biliary stasis, renal failure, or fluid restriction. Most patients with ceftriaxone-induced cholelithiasis are asymptomatic. Although these complications of ceftriaxone therapy are widely known, this broad-spectrum antibiotic is not typically considered a common cause of pancreatitis. However, a few patients report serious complications such as cholecystitis and pancreatitis. 2 We report a case of a 70-year-old man who developed ceftriaxone-induced acute pancreatitis, which was treated with conservative therapy.
CASE
A 70-year-old man presented with general weakness and fever lasting several days. His medical history included hypertension, diabetes mellitus, angina, and gallstones and having CT revealed dilatation and enhancement of the wall of the CBD with sludge and also showed pancreatic swelling and peripancreatic fluid collection (Fig 2) . These findings were observed to be new since the previous imaging study performed 2 weeks prior. We suspected ceftriaxone-induced acute biliary pancreatitis; thus, his antibiotic was switched to ciprofloxacin. Two days after discontinuing ceftriaxone, he showed an improvement in symptoms, and laboratory examinations showed that his serum amylase and lipase levels had returned to reference range. Leukocytosis and elevated CRP were normalized 14 days later. Follow-up CT performed 16 days after discontin- uing ceftriaxone showed interval improvement in pancreatitis and no sludge in the CBD (Fig. 3) . He recovered uneventfully with conservative treatment and was subsequently discharged.
DISCUSSION
Ceftriaxone is primarily excreted through the kidneys, and 10-20% of the drug is excreted in the bile. However, ceftriaxone is known to cause severe adverse events such as cholecystitis, and pancreatitis, and even necrotizing pancreatitis, and a cholecystectomy may be required in a few patients. 1 Globally, four cases of ceftriaxone-associated pancreatitis have been reported in adults. [9] [10] [11] [12] These patients developed acute pancreatitis after 5-10 days of treatment with ceftriaxone (2 g/day). CT showed ceftriaxone-associated pseudolithiasis with pancreatitis in 2 patients, 11, 12 and biliary sludge leakage from the gallbladder into the CBD and pancreatic duct causing pancreatitis in 1. 12 Notably, four cases of ceftriaxone-induced gallbladder pseudolithiasis have been reported in Korea, however no case of ceftriaxone-associated pancreatitis has been reported. [13] [14] [15] Of note, our patient received a large dosage of ceftriaxone over several weeks, which increased his risk of ceftriaxone- 
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